New abdominal injection tested for Tough-to-Treat cancers
NCT ID NCT05438459
Summary
This study is testing a new drug called GAIA-102 for people with advanced stomach or pancreatic cancer that has spread to the lining of the abdomen, causing fluid buildup. The drug is injected directly into the abdomen, either alone or combined with an existing immunotherapy drug (pembrolizumab). The first part of the trial checks for safety and the best dose, while the second part looks at whether the treatment helps patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kyushu University Hospital
RECRUITINGFukuoka, Fukuoka, 812-8582, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.